Lancet Publication: New Analysis Demonstrates Only Small Minority of Severe/Very Severe COPD Patients May Benefit from Adding ICS to SPIRIVA® HANDIHALER® (tiotropium bromide inhalation powder) + LABA Therapy
• New post-hoc analysis shows routine eosinophil blood test could help identify the small minority of severe/very severe patients who may benefit from addition of ICS* • Only 20 percent of patients in WISDOM† study benefited from addition of ICS on top of SPIRIVA® HANDIHALER®‡ and a LABA§ with regards to exacerbation risk reduction • The data analysis, published in Lancet Respiratory Medicine, adds to current debate about appropriate selection of patients for ICS treatment in chronic obstructive pulmonary disease (COPD)
Source: Boehringer Ingelheim Press Releases - Category: Research Source Type: news
More News: Chronic Obstructive Pulmonary | Research | Respiratory Medicine | Spiriva | Study | Tiotropium